Patent details

301231 Product Name: Loncastuximab tesirine

The time of generation of the report may vary depending on the number of the selected files and the pages of each file. If the generation of the consolidated PDF file takes long, you may reduce the number of selected files and proceed with the generation of the PDF in batches.
You have not selected any documents

Basic Information

Publication number:
301231
Type:
Certificate
SPC Type:
Medical
Basic Patent Number:
EP2906298
Status:
SPC granted but not yet in force
Application number:
301231
Procedural language:
Dutch
First Applicant Residence Country:
Switzerland (CH)

Marketing Authorization

Marketing Authorization Number:
EU/1/22/1695
Marketing Authorization Type:
EEA
Marketing Authorization Date:
22/12/2022
Marketing Authorization Country:
European Union (EU)

Dates

Filing date:
08/05/2023
First Marketing Authorization date:
22/12/2022
Grant date:
09/11/2023
Activation date:
Lapsed By Non Payment Annual Fee Date:
Renunciation Date:
NullificationDate:
Registration date:
08/05/2023
SPC/SPC Extension Expiration Date:
21/12/2037
Lapsed By Expiration Date:
Withdrawal date:
Revocation Date:
Invalidity Date:
Withdrawal Market Authorization Date:
Refusal Date:

Applicant/holder

From:
08/05/2023
 
 

 

Name:
Medimmune Limited
Address:
Milstein Building Granta Park, CAMBRIDGE, CAMBRIDGESHIRE CB21 6GH, United Kingdom (GB)

From:
08/05/2023
 
 

 

Name:
ADC Therapeutics SA
Address:
Biopôle Route de la Corniche 3B, 1066 Epalinges, Switzerland (CH)

Agent

Name:
ir. F.A. Geurts c.s.
From:
08/05/2023
Address:
Octrooibureau Vriesendorp & Gaade B.V. Koninginnegracht 19, 2514 AB, Den Haag, Netherlands (NL)
To:

Publication

Bulletin

1

Bulletin Heading:
SPC
Journal edition number:
46/23
Publication date:
15/11/2023
Description:
Applications and granted Supplementary Protection Certificates (or the extensions of the Supplementary Protection Certificates)

2

Bulletin Heading:
SPC
Journal edition number:
19/23
Publication date:
10/05/2023
Description:
Applications and granted Supplementary Protection Certificates (or the extensions of the Supplementary Protection Certificates)

Annual Fee

Annual Fee(s) Due Date:
31/10/2033
Annual Fee Number:
21
Annual Fee Amount:
1600 Euro
Last Annual Payment Date:
Last Annual Fee Paid Number:
Payer:
Filing date Document type Document Description Number of pages File Type
09/11/2023 Certificate Certificate 1 PDF /1/4/9/5/7/0800875941/docs/301231_10_spcmedcertificate20231109123451198.pdf
09/11/2023 Outgoing Correspondence Decision grant 1 PDF /1/4/9/5/7/0800875941/docs/301231_11_575326l504a.pdf
09/08/2023 Incoming Correspondence Paper Accompanying letter incoming document 1 PDF /1/4/9/5/7/0800875941/docs/301231_8_incomingcorrespondencepaper20230809020131072.pdf
27/07/2023 Outgoing Correspondence Letter to applicant 2 PDF /1/4/9/5/7/0800875941/docs/301231_9_557837l173.pdf
08/05/2023 Outgoing Correspondence Confirmation receipt request 1 PDF /1/4/9/5/7/0800875941/docs/301231_0_544305l174.pdf
08/05/2023 SPC Documents Annex SPC 3 PDF /1/4/9/5/7/0800875941/docs/301231_1_supplprotectioncertificate20230508020605820.pdf
08/05/2023 SPC Documents Marketing Authorization SPC 4 PDF /1/4/9/5/7/0800875941/docs/301231_2_supplprotectioncertificate20230508020641341.pdf
08/05/2023 SPC Documents Annex SPC 3 PDF /1/4/9/5/7/0800875941/docs/301231_3_supplprotectioncertificate20230508020706336.pdf
08/05/2023 SPC Documents Summary of the characteristics of the product 16 PDF /1/4/9/5/7/0800875941/docs/301231_4_supplprotectioncertificate20230508020743165.pdf
08/05/2023 SPC Documents Annex SPC 1 PDF /1/4/9/5/7/0800875941/docs/301231_5_supplprotectioncertificate20230508020723521.pdf
08/05/2023 Application Form First filed application form 4 PDF /1/4/9/5/7/0800875941/docs/301231_6_applicationform20230508020526126.pdf
08/05/2023 SPC Documents Annex SPC 9 PDF /1/4/9/5/7/0800875941/docs/301231_7_supplprotectioncertificate20230508022146382.pdf